Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | LRIG1 |
| Gene Name: | LRIG1 |
| Protein Full Name: | Leucine-rich repeats and immunoglobulin-like domai |
| Alias: | DKFZP586O1624; Leucine-rich repeat protein LRIG1; Leucine-rich repeats and immunoglobulin-like domains 1; LIG1; LIG-1; Ortholog of mouse integral membrane glycoprotein LIG-1 |
| Mass (Da): | 119113 |
| Number AA: | 1093 |
| UniProt ID: | Q96JA1 |
| Locus ID: | 26018 |
| COSMIC ID: | LRIG1 |
| Gene location on chromosome: | 3p14.1 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 0.96 |
| Normal role description: | LRIG1 is a Receptor-Tyrosine Kinase suppressor, and plays a role in signal transduction, cell proliferation, migration, invasion apopotosis, and in cell cycle regulation, It is a putative tumour suppressor gene that has been found to be down-regulated in various cancers. The soluble ectodomain of the protein can modulate EGFR signalling and its growth-promoting activity in a paracrine fashion. |
| Commentary on involvement of protein in cancer: | *High LRIG1 expression was significantly associated with short overall and prostate cancer-specific survival for 256 Swedish patients analysed but in an American study, high LRIG1 expression was significantly associated with longer overall survival. |